4.6 Article

Dialysate sodium, serum sodium and mortality in maintenance hemodialysis

期刊

NEPHROLOGY DIALYSIS TRANSPLANTATION
卷 27, 期 4, 页码 1613-1618

出版社

OXFORD UNIV PRESS
DOI: 10.1093/ndt/gfr497

关键词

dialysate; hemodialysis; hyponatremia; modeling; mortality

资金

  1. Satellite Healthcare
  2. Genzyme
  3. NIDDK [DK079056, DK075941]
  4. Astellas

向作者/读者索取更多资源

Background. Individuals with end-stage kidney disease appear to have stable pre-dialysis serum sodium concentrations over time, with lower values associating with increased mortality. Dialysate sodium concentrations have increased over many years in response to shorter treatments, but the relationship between serum sodium, dialysate sodium and outcomes in chronic hemodialysis patients has not yet been systematically examined. Methods. We studied a cohort of 2272 individuals receiving thrice-weekly hemodialysis treatment. Available data included demographics, laboratory and clinical measures, details of the dialysis prescription and 30-month follow-up. We examined the distribution of serum and dialysate sodium among subjects and compared mortality according to dialysate and serum sodium concentrations using Cox regression models. Results. Dialysate sodium concentration varied within and among dialysis centers. The pre-dialysis serum sodium concentration (mean 136.1 mmol/L) did not differ across dialysate sodium concentrations. There was evidence for effect modification for mortality according to differing serum sodium and dialysate sodium concentrations (P = 0.05). For each 4 mmol/L increment in serum sodium, the hazard ratio for death was 0.72 [95% confidence interval (CI) 0.63-0.81] with lower dialysate sodium compared to 0.86 (95% CI 0.75-0.99) for higher dialysate sodium. Higher dialysate sodium concentration was associated with mortality at higher, but not lower, pre-dialysis serum sodium concentrations. Conclusions. The pre-dialysis serum sodium concentration appears to be unaffected by the dialysate sodium concentration. The relationship between serum and dialysate sodium and mortality appears to be variable. Further research is warranted to determine the biological mechanisms of these associations and to re-examine total body sodium handling in hemodialysis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Engineering, Biomedical

Risk of Intradialytic Hypotension by Day of the Week in Maintenance Hemodialysis

Simon Correa, Xavier E. Guerra-Torres, Katherine Scovner Ravi, Suraj S. Mothi, Sushrut S. Waikar, Finnian R. Mc Causland

Summary: Intradialytic hypotension (IDH) is a common complication of hemodialysis (HD) that is associated with increased risk of cardiovascular (CV) events and mortality. This study found that the risk of IDH increases with later days of the dialytic week, and CV events are more common following the longer interdialytic interval.

ASAIO JOURNAL (2022)

Article Surgery

Excess mortality in solid organ transplant recipients hospitalized with COVID-19: A large-scale comparison of SOT recipients hospitalized with or without COVID-19

Karola S. Jering, Martina M. McGrath, Finnian R. Mc Causland, Brian Claggett, Jonathan W. Cunningham, Scott D. Solomon

Summary: Solid-organ transplant recipients hospitalized with COVID-19 have higher odds of complications and in-hospital mortality compared to admissions for other causes, including non-COVID-19 pneumonia. The odds of in-hospital death are 2.5 times higher for SOT recipients with COVID-19 compared to those with non-COVID-19 pneumonia, regardless of the time of hospitalization.

CLINICAL TRANSPLANTATION (2022)

Article Urology & Nephrology

Predialysis serum phosphate and intradialytic hypotension

Katherine Scovner Ravi, Patrick B. Reeves, Simon Correa, Joao Sergio Neves, Sushrut S. Waikar, Suraj S. Mothi, Finnian R. Mc Causland

Summary: The study found that higher pre-HD serum phosphate levels are independently associated with an increased risk of hypotension during hemodialysis sessions, indicating the need for further research to investigate the mechanisms behind this association.

HEMODIALYSIS INTERNATIONAL (2022)

Article Endocrinology & Metabolism

Determinants and Outcomes Associated With Urinary Calcium Excretion in Chronic Kidney Disease

Jing Liu, Maria Clarissa Tio, Ashish Verma, Insa M. Schmidt, Titilayo O. Ilori, Felix Knauf, Finnian R. Mc Causland, Sushrut S. Waikar

Summary: This study aimed to investigate predictors of urinary calcium excretion and its association with adverse clinical outcomes in chronic kidney disease (CKD). The results showed that estimated glomerular filtration rate (eGFR) was positively correlated with 24-hour urinary calcium excretion. The determinants of urinary calcium excretion differed between sexes and levels of CKD. Lower urinary calcium excretion was associated with higher risks of adverse outcomes, but these associations were greatly attenuated or nullified after adjustment for baseline eGFR.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Article Cardiac & Cardiovascular Systems

Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF

Alexander Peikert, Muthiah Vaduganathan, Finnian Mc Causland, Brian L. Claggett, Safia Chatur, Milton Packer, Marc A. Pfeffer, Faiez Zannad, Martin P. Lefkowitz, Burkert Pieske, Hans-Dirk Duengen, John J. V. McMurray, Scott D. Solomon

Summary: The study found that sacubitril/valsartan similarly attenuates the decline of eGFR and reduces clinically relevant kidney events among patients with HFpEF with and without diabetes, compared to renin-angiotensin system inhibitors alone.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Article Cardiac & Cardiovascular Systems

Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure

Finnian R. Mc Causland, Martin P. Lefkowitz, Brian Claggett, Milton Packer, Michele Senni, Mauro Gori, Pardeep S. Jhund, Martina M. McGrath, Jean L. Rouleau, Victor Shi, Karl Swedberg, Muthiah Vaduganathan, Faiez Zannad, Marc A. Pfeffer, Michael Zile, John J. McMurray, Scott D. Solomon

Summary: In patients with heart failure, sacubitril/valsartan reduces the risk of adverse renal outcomes and slows the decline in eGFR, regardless of baseline renal function.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

Article Peripheral Vascular Disease

Association of Different Definitions of Intradialytic Hypertension With Long-Term Mortality in Hemodialysis

Anika T. Singh, Sushrut S. Waikar, Finnian R. Mc Causland

Summary: Intradialytic hypertension in hemodialysis patients is associated with increased mortality risk, but there is no consensus on its definition. This study found that any increase in systolic blood pressure from prehemodialysis to posthemodialysis was associated with the highest adjusted risk of mortality, compared to other threshold-based definitions.

HYPERTENSION (2022)

Article Cardiac & Cardiovascular Systems

Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction A Prespecified Analysis of the DELIVER Randomized Clinical Trial

Finnian R. Mc Causland, Brian L. Claggett, Muthiah Vaduganathan, Akshay S. Desai, Pardeep Jhund, Rudolf A. de Boer, Kieran Docherty, James Fang, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S. P. Lam, Felipe Martinez, Jose F. Kerr Saraiva, Martina M. McGrath, Sanjiv J. Shah, Subodh Verma, Anna Maria Langkilde, Magnus Petersson, John J. McMurray, Scott D. Solomon

Summary: Dapagliflozin has no effect on baseline kidney function in patients with heart failure and a mildly reduced or preserved ejection fraction. Dapagliflozin does not significantly reduce the frequency of kidney composite outcomes, but can slow the decline in eGFR.

JAMA CARDIOLOGY (2023)

Article Medicine, General & Internal

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Natalie Staplin, Richard Haynes, Kaitlin J. Mayne, Alistair J. Roddick, Brendon L. Neuen, Sibylle J. Hauske, Stefan D. Anker, Martina Brueckmann, Javed Butler, David Z. Cherney, Jennifer B. Green, Chih-Chin Liu, Finnian R. McCausland, Darren K. McGuire, John J. McMurray, Milton Packer, Vlado Perkovic, Marc S. Sabatine, Scott D. Solomon, Muthiah Vaduganathan, Christoph Wanner, Stephen D. Wiviott, Faiez Zannad, Hiddo J. L. Heerspink, Sarah Y. A. Ng, Doreen Zhu, Parminder Judge, David Preiss, Martin J. Landray, Colin Baigent, Jonathan R. Emberson, William G. Herrington, Deepak L. Bhatt, Bruce Neal, Silvio E. Inzucchi, Meg J. Jardine, Kenneth W. Mahaffey, David C. Wheeler

Summary: This study provides evidence that SGLT2 inhibitors can reduce the risk of kidney disease progression and acute kidney injury, not only in patients with type 2 diabetes at high cardiovascular risk, but also in patients with chronic kidney disease or heart failure regardless of diabetes status, primary kidney disease, or kidney function.

LANCET (2022)

Article Transplantation

Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials

Ajay K. Singh, Finnian R. Mc Causland, Brian L. Claggett, Christoph Wanner, Andrzej Wiecek, Michael B. Atkins, Kevin Carroll, Vlado Perkovic, John J. McMurray, Janet Wittes, Steven Snapinn, Allison Blackorby, Amy Meadowcroft, Tara Barker, Tara DiMino, Stephen Mallett, Alexander R. Cobitz, Scott D. Solomon

Summary: Different dosing intervals were used in the study, which resulted in different risks of cancer-related adverse events for daprodustat compared to darbepoetin in patients with CKD. However, no excess risk of cancer-related adverse events was observed in dialysis patients.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Editorial Material Urology & Nephrology

To Cool the Dialysate or Not? Question Answered?

Finnian R. Mc Causland, David M. Charytan

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2023)

Review Peripheral Vascular Disease

Time of hemodialysis and risk of intradialytic hypotension and intradialytic hypertension in maintenance hemodialysis

Murad Alostaz, Simon Correa, Gavin S. Lundy, Sushrut S. Waikar, Finnian R. Mc Causland

Summary: Patients who undergo hemodialysis in the morning have a lower risk of intradialytic hypotension and a higher risk of intradialytic hypertension compared to those who undergo dialysis in the afternoon.

JOURNAL OF HUMAN HYPERTENSION (2023)

Article Urology & Nephrology

Effects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial

Finnian R. Mc Causland, Jesse Y. Hsu, Jonathan Himmelfarb, Talat Alp Ikizler, Dominic S. Raj, Rajnish Mehrotra, Sushrut S. Waikar, Paul L. Kimmel, Alan S. Kliger, Laura M. Dember, David M. Charytan

Summary: In a post hoc analysis, it was found that spironolactone treatment resulted in a higher frequency of bradycardia and conduction blocks in patients receiving maintenance hemodialysis. Close monitoring is necessary for these patients while awaiting definitive trial results.

KIDNEY360 (2023)

Meeting Abstract Cardiac & Cardiovascular Systems

Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial

F. McCausland, A. Singh, B. Claggett, K. Carroll, J. Wittes, J. J. V. McMurray, V. Perkovic, S. Snappin, R. Lopes, S. Solomon

EUROPEAN HEART JOURNAL (2022)

Meeting Abstract Cardiac & Cardiovascular Systems

EFFECTS OF SACUBITRIL/VALSARTAN VERSUS VALSARTAN ON RENAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE WITH PRESERVED EJECTION FRACTION: PARAGON-HF

Alexander Peikert, Muthiah Vaduganathan, Finnian McCausland, Brian Claggett, Safia Chatur, Milton Packer, Marc A. Pfeffer, Faiez Zannad, Martin Lefkowitz, Burkert Mathias Pieske, Hans-Dirk Dungen, John J. V. McMurray, Scott D. Solomon

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

暂无数据